3 results
Approved WMOCompleted
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
Approved WMOPending
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…
Approved WMORecruiting
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.